Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VHL | P40337 | 20/20 | 0.53 |
| ▸ | ELOC | Q15369 | 3/20 | 0.49 |
| ▸ | ELOB | Q15370 | 3/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24762071 | 0.95 | VHL (0.50) | VHLELOCELOBHDAC3HDAC1 | |
| SCHEMBL18063876 | 0.92 | VHL (0.60) | VHLELOCELOBHDAC3HDAC1 | |
| SCHEMBL18063878 | 0.92 | VHL (0.60) | VHLELOCELOBHDAC3HDAC1 | |
| SCHEMBL20133083 | 0.91 | VHL (0.46) | VHLELOCELOBHDAC3HDAC1 | |
| SCHEMBL20133017 | 0.87 | VHL (0.64) | VHLELOCELOB | |
| SCHEMBL20330400 | 0.86 | VHL (0.61) | VHLELOCELOB | |
| SCHEMBL21899138 | 0.86 | VHL (0.51) | VHLELOCELOBHDAC3HDAC1 | |
| SCHEMBL20330412 | 0.86 | VHL (0.63) | VHLELOCELOBHDAC3HDAC1 | |
| SCHEMBL22789493 | 0.85 | VHL (0.76) | VHLELOCELOBHDAC3HDAC1 | |
| SCHEMBL21025621 | 0.85 | VHL (0.76) | VHLELOCELOBHDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11191741-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | ARVINAS OPERATIONS, INC. (US) | 2021-12-07 | — | — | US | disclosed |
| US-20180177750-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ENHANCER OF ZESTE HOMOLOG 2 POLYPEPTIDE | ARVINAS OPERATIONS, INC. | 2018-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11191741-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | CRBN, MDM2, VHL | VHL 3/4885ELOC 711/4885ELOB 391/4885 |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | CRBN, MDM2, VHL | VHL 3/4885ELOC 711/4885ELOB 391/4885 |
| US-20180177750-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ENHANCER OF ZESTE HOMOLOG 2 POLYPEPTIDE | CRBN, MDM2, VHL | VHL 3/4885ELOC 711/4885ELOB 391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.